Background: Chronic obstructive pulmonary disease (COPD) is the only cause of mortality and morbidity with an increasing incidence. Adiponectin has recently gained the spotlight for its possible association with COPD or its exacerbation. This study evaluated the association of serum and alveolar adiponectin levels with COPD-related variables. Materials and Methods: This analytical cross-sectional study was carried out on 45 COPD patients. Number of cigarettes smoked (packs), years of smoking, number of disease exacerbations per year and BMI were all recorded. Patients underwent spirometry and their disease severity was determined based on BODE index. Venous blood sample was obtained to measure the adiponectin serum level, ESR and CRP. Bronchoscopy and BAL were performed as well and alveolar secretions were collected to assess the alveolar fluid level of adiponectin.
INTRODUCTION
COPD is defined as progressive and irreversible airflow limitation in airways (1) . At present, COPD is the 4 th cause of death in the United States and the only cause of morbidity and mortality with an increasing incidence (2) . This study evaluated the association of serum and alveolar adiponectin levels with COPD-related variables.
MATERIALS AND METHODS
This analytical cross-sectional study was conducted on COPD patients. Patients with absolute contraindications for bronchoscopy such as treatment-resistant hypoxia, treatment-resistant arrhythmia, patient's non-compliance and comorbidities related to adipose tissue hormones such as diabetes mellitus, metabolic syndrome, and obesity were excluded from the study and a total of 45 patients were evaluated. The study design was thoroughly explained to subjects, patients' questions were answered and written informed consent was obtained from them.
The study was carried out in 4 phases. In the first phase, number of smoked cigarettes (packs), years of smoking and number of exacerbations per year were recorded. Pack-year was calculated by multiplying the number of cigarette packs smoked per day by the number of smoking years. Height (using a tape measure) and weight (using digital scale) of patients were measured and body mass index (BMI) was calculated.
In the 2 nd phase, subjects underwent spirometry (Spirometer, Japan) and severity of airway constriction was determined based on FEV1. Patients were then subjected to 6-minute walk-test and the distance walked was determined in meter. Severity of dyspnea was calculated based on patient's history and MMRC table and scored from 0 to 4. Eventually, their disease severity was determined using BODE Index (MMRC, 6-minute walk distance, BMI, FEV1)(score 0 to 10).
In the third phase, 5 ml of venous blood sample was Obtained data were statistically analyzed. Descriptive statistics were used for description of data and Pearson's Healthy control group was not used in our study because bronchoscopy is an invasive and costly procedure and there was no healthy volunteer for the study. Thus, adiponectin serum level of patients was compared with the normal range mentioned in previous studies (5-10 μg/ml).
On the other hand, no normal range was found for alveolar adiponectin level in the literature and thus, we could not make any comparisons in this respect. 
